Pathway Activity Profiling of Growth Factor Receptor Network and Stemness Pathways Differentiates Metaplastic Breast Cancer Histological Subtypes

Overview

Journal BMC Cancer

Publisher Biomed Central

Specialty Oncology

Date 2019 Sep 7

PMID 31488082

Citations 14

Authors

Jasmine A McQuerry

David F Jenkins

Susan E Yost

Yuqing Zhang

Daniel Schmolze

W Evan Johnson

Yuan Yuan

Andrea H Bild

Affiliations

Soon will be listed here.

Abstract

Background: Gene expression profiling of rare cancers has proven challenging due to limited access to patient materials and requirement of intact, non-degraded RNA for next-generation sequencing. We customized a gene expression panel compatible with degraded RNA from formalin-fixed, paraffin-embedded (FFPE) patient cancer samples and investigated its utility in pathway activity profiling in patients with metaplastic breast cancer (MpBC).

Methods: Activity of various biological pathways was profiled in samples from nineteen patients with MpBC and 8 patients with invasive ductal carcinoma with triple negative breast cancer (TNBC) phenotype using a custom gene expression-based assay of 345 genes.

Results: MpBC samples of mesenchymal (chondroid and/or osteoid) histology demonstrated increased SNAI1 and BCL2L11 pathway activity compared to samples with non-mesenchymal histology. Additionally, late cornified envelope and keratinization genes were downregulated in MpBC compared to TNBC, and epithelial-to-mesenchymal transition (EMT) and collagen genes were upregulated in MpBC. Patients with high activity of an invasiveness gene expression signature, as well as high expression of the mesenchymal marker and extracellular matrix glycoprotein gene SPARC, experienced worse outcomes than those with low invasiveness activity and low SPARC expression.

Conclusions: This study demonstrates the utility of gene expression profiling of metaplastic breast cancer FFPE samples with a custom counts-based assay. Gene expression patterns identified by this assay suggest that, although often histologically triple negative, patients with MpBC have distinct pathway activation compared to patients with invasive ductal TNBC. Incorporation of targeted therapies may lead to improved outcome for MpBC patients, especially in those patients expressing increased activity of invasiveness pathways.

Citing Articles

Highly effective batch effect correction method for RNA-seq count data.

Zhang X Comput Struct Biotechnol J. 2025; 27():58-64.

PMID: 39802213 PMC: 11718288. DOI: 10.1016/j.csbj.2024.12.010.

Starfysh integrates spatial transcriptomic and histologic data to reveal heterogeneous tumor-immune hubs.

He S, Jin Y, Nazaret A, Shi L, Chen X, Rampersaud S Nat Biotechnol. 2024; 43(2):223-235.

PMID: 38514799 PMC: 11415552. DOI: 10.1038/s41587-024-02173-8.

Lipid Peroxidation and Type I Interferon Coupling Fuels Pathogenic Macrophage Activation Causing Tuberculosis Susceptibility.

Yabaji S, Zhernovkov V, Araveti P, Lata S, Rukhlenko O, Al Abdullatif S bioRxiv. 2024; .

PMID: 38496444 PMC: 10942339. DOI: 10.1101/2024.03.05.583602.

Chemotherapy is of prognostic significance to metaplastic breast cancer.

Zhang M, Yuan J, Wang M, Zhang M, Chen H Sci Rep. 2024; 14(1):1210.

PMID: 38216630 PMC: 10786888. DOI: 10.1038/s41598-024-51627-1.

pyComBat, a Python tool for batch effects correction in high-throughput molecular data using empirical Bayes methods.

Behdenna A, Colange M, Haziza J, Gema A, Appe G, Azencott C BMC Bioinformatics. 2023; 24(1):459.

PMID: 38057718 PMC: 10701943. DOI: 10.1186/s12859-023-05578-5.

References

Al-Hajj M, Wicha M, Benito-Hernandez A, Morrison S, Clarke M . Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A. 2003; 100(7):3983-8. PMC: 153034. DOI: 10.1073/pnas.0530291100. View

Boquest A, Shahdadfar A, Fronsdal K, Sigurjonsson O, Tunheim S, Collas P . Isolation and transcription profiling of purified uncultured human stromal stem cells: alteration of gene expression after in vitro cell culture. Mol Biol Cell. 2005; 16(3):1131-41. PMC: 551479. DOI: 10.1091/mbc.e04-10-0949. View

Hennessy B, Giordano S, Broglio K, Duan Z, Trent J, Buchholz T . Biphasic metaplastic sarcomatoid carcinoma of the breast. Ann Oncol. 2006; 17(4):605-13. DOI: 10.1093/annonc/mdl006. View

Lien H, Hsiao Y, Lin Y, Yao Y, Juan H, Kuo W . Molecular signatures of metaplastic carcinoma of the breast by large-scale transcriptional profiling: identification of genes potentially related to epithelial-mesenchymal transition. Oncogene. 2007; 26(57):7859-71. DOI: 10.1038/sj.onc.1210593. View

Geiss G, Bumgarner R, Birditt B, Dahl T, Dowidar N, Dunaway D . Direct multiplexed measurement of gene expression with color-coded probe pairs. Nat Biotechnol. 2008; 26(3):317-25. DOI: 10.1038/nbt1385. View

Tse C, Shoemaker A, Adickes J, Anderson M, Chen J, Jin S . ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res. 2008; 68(9):3421-8. DOI: 10.1158/0008-5472.CAN-07-5836. View

Kusafuka K, Muramatsu K, Kasami M, Kuriki K, Hirobe K, Hayashi I . Cartilaginous features in matrix-producing carcinoma of the breast: four cases report with histochemical and immunohistochemical analysis of matrix molecules. Mod Pathol. 2008; 21(10):1282-92. DOI: 10.1038/modpathol.2008.120. View

Jung S, Kim H, Nam B, Min S, Lee S, Park C . Worse prognosis of metaplastic breast cancer patients than other patients with triple-negative breast cancer. Breast Cancer Res Treat. 2010; 120(3):627-37. DOI: 10.1007/s10549-010-0780-8. View

Phong M, Van Horn R, Li S, Tucker-Kellogg G, Surana U, Ye X . p38 mitogen-activated protein kinase promotes cell survival in response to DNA damage but is not required for the G(2) DNA damage checkpoint in human cancer cells. Mol Cell Biol. 2010; 30(15):3816-26. PMC: 2916406. DOI: 10.1128/MCB.00949-09. View

10.

Lee S, Shen G, Jung Y, Lee S, Chung J, Kim H . Antitumor effect of novel small chemical inhibitors of Snail-p53 binding in K-Ras-mutated cancer cells. Oncogene. 2010; 29(32):4576-87. DOI: 10.1038/onc.2010.208. View

11.

Gwin K, Buell-Gutbrod R, Tretiakova M, Montag A . Epithelial-to-mesenchymal transition in metaplastic breast carcinomas with chondroid differentiation: expression of the E-cadherin repressor Snail. Appl Immunohistochem Mol Morphol. 2010; 18(6):526-31. DOI: 10.1097/PAI.0b013e3181e8d54b. View

12.

Taube J, Herschkowitz J, Komurov K, Zhou A, Gupta S, Yang J . Core epithelial-to-mesenchymal transition interactome gene-expression signature is associated with claudin-low and metaplastic breast cancer subtypes. Proc Natl Acad Sci U S A. 2010; 107(35):15449-54. PMC: 2932589. DOI: 10.1073/pnas.1004900107. View

13.

Chen I, Lin C, Huang C, Lien H, Hsu C, Kuo W . Lack of efficacy to systemic chemotherapy for treatment of metaplastic carcinoma of the breast in the modern era. Breast Cancer Res Treat. 2011; 130(1):345-51. DOI: 10.1007/s10549-011-1686-9. View

14.

Anastassiou D, Rumjantseva V, Cheng W, Huang J, Canoll P, Yamashiro D . Human cancer cells express Slug-based epithelial-mesenchymal transition gene expression signature obtained in vivo. BMC Cancer. 2012; 11:529. PMC: 3268117. DOI: 10.1186/1471-2407-11-529. View

15.

Norton N, Sun Z, Asmann Y, Serie D, Necela B, Bhagwate A . Gene expression, single nucleotide variant and fusion transcript discovery in archival material from breast tumors. PLoS One. 2013; 8(11):e81925. PMC: 3838386. DOI: 10.1371/journal.pone.0081925. View

16.

Shah P, Gau Y, Sabnis G . Histone deacetylase inhibitor entinostat reverses epithelial to mesenchymal transition of breast cancer cells by reversing the repression of E-cadherin. Breast Cancer Res Treat. 2013; 143(1):99-111. DOI: 10.1007/s10549-013-2784-7. View

17.

Javaid S, Zhang J, Anderssen E, Black J, Wittner B, Tajima K . Dynamic chromatin modification sustains epithelial-mesenchymal transition following inducible expression of Snail-1. Cell Rep. 2013; 5(6):1679-89. PMC: 4034764. DOI: 10.1016/j.celrep.2013.11.034. View

18.

Liu S, Cong Y, Wang D, Sun Y, Deng L, Liu Y . Breast cancer stem cells transition between epithelial and mesenchymal states reflective of their normal counterparts. Stem Cell Reports. 2014; 2(1):78-91. PMC: 3916760. DOI: 10.1016/j.stemcr.2013.11.009. View

19.

Lien H, Lee Y, Jeng Y, Lin C, Lu Y, Yao Y . Differential expression of hyaluronan synthase 2 in breast carcinoma and its biological significance. Histopathology. 2014; 65(3):328-39. DOI: 10.1111/his.12390. View

20.

Stricker T, Morales La Madrid A, Chlenski A, Guerrero L, Salwen H, Gosiengfiao Y . Validation of a prognostic multi-gene signature in high-risk neuroblastoma using the high throughput digital NanoString nCounter™ system. Mol Oncol. 2014; 8(3):669-78. PMC: 4004665. DOI: 10.1016/j.molonc.2014.01.010. View